Angiogenesis and non-small cell lung cancer.
Lung cancer is the commonest cause of cancer death in the western world. Recent evidence suggests that angiogenesis is related to poor prognosis in many solid tumours including non-small cell lung cancer. Angiogenesis is controlled by a complex interaction between growth and apoptotic factors, proteases and adhesion molecules. The angiogenic process may prove a target for novel therapies such as matrix metalloproteinase inhibitors, growth factor antisense RNA, growth factor receptor antagonists and naturally occurring antiangiogenic peptides. These agents may be used alone or in combination with traditional chemotherapy, radiotherapy and surgery.
Cox
G
G
University Department of Medical Oncology, Leicester Royal Infirmary, UK.
Jones
J L
JL
Walker
R A
RA
Steward
W P
WP
O'Byrne
K J
KJ
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D017209:Apoptosis; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D020782:Matrix Metalloproteinases / Q000378:metabolism; D009389:Neovascularization, Pathologic
D020533:Angiogenesis Inhibitors; D006133:Growth Substances; D020782:Matrix Metalloproteinases